Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Text and Data Mining valid from 2018-08-16
16 August 2018
Compliance with Ethical Standards
No funding was received for the preparation of this manuscript.
Dr. Frapaise has no conflicts of interest to declare.